6.81

1.79% 0.12

Adicet Bio Inc (ACET)

Overview News Price History Option Chain Financials Discussions Forecast

Adicet Bio Inc stock is traded at $6.81, with a volume of 76,440. It is up +1.79% in the last 24 hours and down -8.10% over the past month. Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. It is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. The company's main product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, and is being developed for the potential treatment of autoimmune diseases. Additionally, it is pursuing ADI-212, a next-generation gene-edited and armored clinical candidate designed to target prostate-specific membrane antigen (PSMA).

Previous Close:

$6.69

Open:

$6.72

24h Volume:

76,440

Relative Volume:

0.45

Market Cap:

$65.35M

Revenue:

$24.99M

Net Income/Loss:

$-116.80M

P/E Ratio:

-0.5062

EPS:

-13.4543

Net Cash Flow:

$-96.98M

1W Performance:

-1.73%

1M Performance:

-8.10%

6M Performance:

-49.26%

1Y Performance:

-51.91%

1-Day Range:

$6.55

$7.00

1-Week Range:

$6.485

$7.115

52-Week Range:

$6.4066

$17.44

Adicet Bio Inc Stock (ACET) Company Profile

Name

Adicet Bio Inc

Sector

Healthcare (1114)

Industry

Biotechnology (623)

Phone

617-482-2333

Address

131 DARTMOUTH STREET, BOSTON

Employee

102

Twitter

Next Earnings Date

2026-03-12

Latest SEC Filings

ACET's Discussions on Twitter

Compare ACET vs VRTX, REGN, ALNY, ARGX, INSM

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ACET Adicet Bio Inc	6.81	65.35M	24.99M	-116.80M	-96.98M	-13.45
VRTX Vertex Pharmaceuticals Inc	454.97	115.58B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	749.47	79.23B	14.34B	4.50B	3.77B	41.56
ALNY Alnylam Pharmaceuticals Inc	328.70	43.59B	3.71B	313.75M	465.38M	2.2571
ARGX Argen X Se Adr	697.05	43.26B	4.16B	1.29B	734.26M	19.58
INSM Insmed Inc	148.31	31.97B	606.42M	-1.28B	-997.58M	-6.403

Adicet Bio Inc Stock (ACET) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Sep-30-24	Resumed	Guggenheim	Buy
Sep-11-24	Downgrade	H.C. Wainwright	Buy → Neutral
Jun-27-23	Downgrade	Guggenheim	Buy → Neutral
Jun-27-23	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
Jun-01-23	Downgrade	JP Morgan	Overweight → Neutral
Sep-21-22	Initiated	JP Morgan	Overweight
Mar-31-22	Initiated	SMBC Nikko	Outperform
Mar-08-22	Initiated	Truist	Buy
Mar-04-22	Initiated	Jefferies	Buy
May-18-21	Initiated	BTIG Research	Buy
Apr-23-21	Initiated	H.C. Wainwright	Buy
Apr-14-21	Initiated	Canaccord Genuity	Buy
Apr-08-21	Initiated	Guggenheim	Buy
Nov-04-20	Initiated	B. Riley Securities	Buy
Oct-27-20	Initiated	JMP Securities	Mkt Outperform
Oct-16-20	Initiated	Wedbush	Outperform

View All

Adicet Bio Inc Stock (ACET) Latest News

Mar 25, 2026

H.C. Wainwright cuts Adicet Bio stock price target on higher discount rate By Investing.com - Investing.com South Africa

Mar 23, 2026

H.C. Wainwright cuts Adicet Bio stock price target on higher discount rate - Investing.com

Mar 23, 2026

Adicet Bio (NASDAQ:ACET) Price Target Cut to $27.00 by Analysts at HC Wainwright - MarketBeat

Mar 23, 2026

Mar 22, 2026

Is Adicet Bio Inc currently under institutional pressure2026 Bull vs Bear & Free Accurate Trade Setup Notifications - baoquankhu1.vn

Mar 22, 2026

Mar 19, 2026

ACET Stock Price, Quote & Chart | ADICET BIO INC (NASDAQ:ACET) - ChartMill

Mar 19, 2026

Mar 17, 2026

Analysts Offer Insights on Healthcare Companies: Adicet Bio (ACET), Teleflex (TFX) and Medacta Group SA (OtherMEDGF) - The Globe and Mail

Mar 17, 2026

IPO Launch: Is Adicet Bio Inc on track to beat earningsWeekly Trend Report & Community Consensus Trade Signals - baoquankhu1.vn

Mar 17, 2026

Mar 15, 2026

Guggenheim Keeps Their Buy Rating on Adicet Bio (ACET) - The Globe and Mail

Mar 15, 2026